Navigation Links
Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
Date:9/19/2007

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from completed studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against a variety of susceptible and resistant strains of gram- positive bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL. All posters highlighted below are being presented at 12:15 pm CDT.

Poster E-1617 is entitled "In Vitro Activity Profile of Oritavancin (ORI) Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative." In this study, researchers examined clinical isolates of Staphylococcus aureus (n=5,008) and coagulase-negative staphylococci (n=862) collected in 2005-2006 from hospital sites in the U.S., Europe and Israel. Oritavancin was active against all staphylococcal isolates, including those with specific resistance phenotypes and including multi-drug resistant S. aureus, which were resistant to three or more of the following agents: ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin, quinupristin- dalfopristin, trimethoprim-sulfa, vancomycin, daptomycin, and linezolid. Results from this study demonstrated that oritavancin had potent in vitro activity against a wide spectrum of staphylococci likely to be encountered in a variety of clinical settings.

Poster E-1613, entitled "In Vitro Activity Profile of Oritavancin (ORI) Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents," compared the activity of oritavancin to vancomycin and teicoplanin against a diverse collection of staphylococci and enterococci, including strains with elevated MICs to linezolid, daptomycin, and/or vancomycin, as well as strains of streptococci. Bacterial isolates included S. aureus (n=35), coagulase-negative staphylococci (n=21), Enterococcus faecalis (
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... of Regulatory Submissions Leadership Strengthened with Clinical ... Trials Services and Standards-Based Data Management, WHIPPANY, ... (ISI) announced today it agreed to terms to ... industry moving to,standards-based regulatory submissions, the acquisition further ...
... the First Hsp90 Inhibitor to Enter Registration Trials, ... KOSN ) today announced that it has successfully,reached a ... on the design of its TIME-1 clinical trial, a ... a treatment for patients with,multiple myeloma. Through the FDA,s ...
Cached Medicine Technology:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:5/20/2013)... Nashville, TN (PRWEB) May 20, 2013 Along ... Warren Melamed has remained a fervent proponent of regular ... appropriate brushing and flossing twice a day. While these recommendations ... of tooth decay reveal that most adults and children are ... patients must find a new way to break into the ...
(Date:5/20/2013)... Senior Solutions Management Group (SSMG), a ... Southeast, today announced that four of its Resident Assistants ... communities have received The Caring Heart Award from Alzheimer’s ... Loudon, Nicole Braden from River Oaks Place in Loudon, ... and Meghan McCormick from Wellspring Senior Living in Knoxville ...
(Date:5/20/2013)... 2013 The main objective for the present ... into a single comprehensive report. The objective was to ... this industry. Thus, it is timely to examine the ... an urgent need in the life science industry for technologies ... in a high-throughput, multiplex and low-cost way. Proteomic technologies ...
(Date:5/20/2013)... Idol lash has designed its brand new ... eyelashes in a matter of few weeks. It is completely ... an extra pack offer to help more women achieve broad ... on the Idol lash official website. , Numerous trials were ... density up to 82% in just a few weeks. According ...
(Date:5/20/2013)... The Semi Truck Accident Victims ... free service for an innocent victim of a catastrophic ... state our services are unparalleled. What this means is ... victim of a passenger vehicle involved in a semi ... Virginia, Ohio, New Jersey, Indiana, Maryland, Georgia, Nebraska, Kansas, ...
Breaking Medicine News(10 mins):Health News:New AirFloss Product Offers Oral Hygiene Innovation, Dental Professional Warren Melamed Comments 2Health News:Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 3Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2Health News:Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response 2
... swallowing the mobile phone by a 24 year women was an ... // The Blue Spring Police are investigated the incident in which ... phone during an argument with her boy friend in which she ... friend. Police got a phone call from her boyfriend that her ...
... Hewitt, the Health Secretary of the UK has imposed a ... //This move has raised doubts as to whether the private ... the NHS will be put into operation. ,The ... ?1 billion plan has been questioned by Ms Hewitt. The ...
... erythematosus (lupus) is a disease in which the body's ... the skin, joints and internal organs.// A study has ... take oral contraceptives safely without any complications like increased ... that characterize the disease. ,The study was ...
... scanner has been developed for premature and newborn babies that ... how the baby brain is working. ,Currently, there are ... Magnetic resonance imaging (MRI) can provide data on brain ... of risk. ,The alternative, ultrasound, can be performed ...
... health benefits of milk thistle, an herbal remedy employed in ... recent study highlighting the lack of evidence for its safety ... for thistle milk, with over 1 million people suffering from ... worldwide. ,The research team analyzed the results of ...
... been passed by the Food and Drug Administration (FDA) saying that ... to be mentioned in the label of the product. ... milk, eggs, fish, crustaceans, wheat, tree nuts, soybeans and peanuts. ... allergies are one of the major causes of death in US. ...
Cached Medicine News:Health News:Milk Thistle Not An Effective Cure For Liver Disease 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: